EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune checkpoint expression and relationships to anti‐PD‐L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice

Myrna G Garcia, Yilun Deng, Clare Murray, Ryan M Reyes iD, Alvaro Padron, Haiyan Bai, Aravind Kancharla, Harshita Gupta, Shai Shen-Orr, Tyler J Curiel iD

Aging and Cancer · 2022-03 · 3 (1) · 68-83

DOI: 10.1002/aac2.12045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging and Cancer, online erschienen am 25.02.2022. Verfasst von Myrna G Garcia und 9 weiteren Autor:innen. Beteiligte Einrichtung: South Texas Medical Scientist Training Program, University of Texas Health, San Antonio, Texas, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Aging is the biggest cancer risk, and immune checkpoint (IC) inhibition (ICI) is a revolutionary cancer immunotherapy approach. Nonetheless, there are limited preclinical/clinical data regarding aging effects on ICI outcomes or age effects on IC expression in different organs or tumors.

Methods

Flow cytometry assessed IC on immune and non‐immune cells in various organs in young and aged BL6 mice. Comparisons: aged versus young naïve WT versus interferon‐γ KO mice and WT challenged with B16F10 melanoma and treated with αPD‐1 or αPD‐L1 ICI. We co‐cultured young and aged T cells and myeloid cells in vitro and used OMIQ analyses to test cell–cell interactions. Results αPD‐1 ICI treated melanoma in young and aged hosts, whereas αPD‐L1 ICI was only effective in young. We found considerable, previously undescribed age effects on expression of various IC molecules participating in the ICI treatment, including PD‐1, PD‐L1, PD‐L2, and CD80, in distinct organs and in the tumor. These data help explain differential ICI efficacy in young and aged hosts. Host interferon‐γ influenced age effects on IC expression in both directions depending on specific IC molecule and tissue. IC expression was further affected by tumor challenge on immune, non‐immune, and tumor cells in tumor and other organs. In in vitro co‐culture, αPD‐1 versus αPD‐L1 distinctly influenced polyclonal T cells in young versus aged, suggesting mechanisms for distinct age‐related ICI outcomes.

Conclusion

Age affects IC expression on specific immune cells in an organ‐ and tissue‐specific manner. ICs were generally higher on aged immune cells. High immune‐cell PD‐1 could help explain αPD‐1 efficacy in aged. High co‐expression of CD80 with PD‐L1 on dendritic cells could help explain lack of αPD‐L1 efficacy in aged hosts. Factors other than myeloid cells and interferon‐γ also affect age‐related IC expression and T cell function, meriting additional studies.

Schlagwörter

Stichwörter der Autor:innen

PD-1PD-L1agecancer immunotherapyimmune checkpointsinterferon-γ

Autor:innen und Institutionen

  • South Texas Medical Scientist Training Program, University of Texas Health, San Antonio, Texas, USA.
  • Graduate School of Biomedical Sciences, University of Texas Health, San Antonio, Texas, USA.
  • Department of Medicine, University of Texas Health, San Antonio, Texas, USA.
  • Senda Biosciences, Cambridge, MA, USA.
  • Technion, Israel Institute of Technology, Haifa, Israel.
  • Clayton Foundation for Research, Houston, Texas, USA.

ORCID-Profile: Ryan M Reyes, Tyler J Curiel

Förderung

  • NIA NIH HHS
  • NIGMS NIH HHS
  • NCATS NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • National Center for Advancing Translational Sciences

Zitieren

APA

Garcia, M. G., Deng, Y., Murray, C., Reyes, R. M., Padron, A., Bai, H., Kancharla, A., Gupta, H., Shen-Orr, S., & Curiel, T. J. (2022). Immune checkpoint expression and relationships to anti‐PD‐L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. Aging and Cancer, 3(1), 68-83. https://doi.org/10.1002/aac2.12045

Vancouver

Garcia MG, Deng Y, Murray C, Reyes RM, Padron A, Bai H, et al. Immune checkpoint expression and relationships to anti‐PD‐L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. Aging and Cancer. 2022;3(1):68-83. doi:10.1002/aac2.12045

BibTeX
@article{Garcia2022,
  author = {Garcia, Myrna G and Deng, Yilun and Murray, Clare and Reyes, Ryan M and Padron, Alvaro and Bai, Haiyan and Kancharla, Aravind and Gupta, Harshita and Shen-Orr, Shai and Curiel, Tyler J},
  title = {Immune checkpoint expression and relationships to anti‐PD‐L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice},
  journal = {Aging and Cancer},
  year = {2022},
  volume = {3},
  number = {1},
  pages = {68--83},
  doi = {10.1002/aac2.12045}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche